The Latest Breaking News from FDA

People are living longer and looking for ways to ease the symptoms of aging, according to a medical marijuana expert.

The healthcare industry is poised to grow rapidly due to the rising need for medical aid, government initiatives, and increasing chronic diseases contributing to overall stability. Given the industry’s promising prospects, investors could consider buying quality healthcare stocks: UnitedHealth Group (UNH), Johnson & Johnson (JNJ), and AbbVie (ABBV), with strong…

The agency's inscrutable approach to harm-reducing nicotine products sacrifices consumer choice and public health on the altar of youth protection.

The U.S. stock is inadequate for a H5N1 pandemic. It’s time to ramp up solutions.

Argenx stock surged Monday after the FDA approved its drug, Vyvgart Hytrulo, for patients with an autoimmune condition known as CIDP.

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Testing failures are a key reason the U.S. fared so poorly with COVID. Are we repeating these mistakes with H5N1?

The Food and Drug Administration has authorized the first menthol-flavored electronic cigarettes for adult smokers

FDA authorizes first menthol e-cigarettes for adult smokers, sparking debate on harm reduction and youth appeal in vaping industry.

The Nasdaq and S&P 500 backed off fresh record highs as Nvidia and AI chip stocks retreated late in the week.

This biotech company has some promising candidates in its pipeline. Could this minor setback slow the company's progress?